Tischer B, Huber R, Kraemer M & Lacouture ME. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Support Care Cancer 2017; 25:651–660.
https://doi.org/10.1007/s00520-016-3419-4
Lacouture ME, Mitchell EP, Piperdi B, Pillai VM, Shearer H, Iannotti N, Xu F, & Yassine M. Skin toxicity evaluation protocol with Panitumumab (STEPP), a Phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and Quality of Life in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2010; 28:1351-1357.
https://doi.org/10.1200/JCO.2008.21.7828
Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079–1095
https://doi.org/10.1007/s00520-011-1197-6
Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C. & Mitchell E. Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: systematic review. Clin Colorectal Cancer. 2018 ;17(2):85–96.
https://doi.org/10.1016/j.clcc.2017.12.004
Lacouture ME, Maitland ML, Segaert S, et al. A proposed EGFR inhibitor dermatologic adverse event specific grading scale from the MASCC Skin Toxicity Study Group. Support Care Cancer. 2010;18(4):509–522.
https://doi.org/10.1007/s00520-009-0744-x
Lichtenberger BM, Gerber PA, Holcmann M, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med. 2013;5(199):199ra111.
https://doi.org/10.1126/scitranslmed.3005886
Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol. 2003;163(1):303–312.
https://doi.org/10.1016/S0002-9440(10)63654-1
Ong MM, Dusza SW, Sugarman R, Kazi R. Association between acneiform eruption grade and survival outcomes in EGFRi-treated metastatic colorectal cancer patients: A retrospective cohort study. J Am Acad Dermatol. 2026 Jan;94(1):314-316.
https://doi.org/10.1016/j.jaad.2025.07.076
Apalla Z, Freites-Martinez A, Boers-Doets CB, et al. Management of epidermal growth factor receptor inhibitor-related acneiform rash: a position paper based on the first Europe/USA Delphi consensus process.
J Eur Acad Dermatol Venereol. 2024;38(12):2349–2365.
https://doi.org/10.1111/jdv.20391
Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. PAIN 2014;155 : 2461–2470.
https://doi.org/10.1016/j.pain.2014.09.020
Hershman DL, Weimer LH, Wang A et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat (2011) 125 :767–774.
https://doi.org/10.1007/s10549-010-1278-0
Hanai A, Ishiguro H, Sozu T et al. Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: prospective self-controlled trial. JNCI J Natl Cancer Inst (2018) 110(2): djx178
https://doi.org/10.1093/jnci/djx178
Delmotte JB, Tutakhail A, Abdallah K, et al. Electrochemical skin conductance as a marker of painful oxaliplatin-induced peripheral neuropathy. Neurology Research International: 2018; 1-9.
https://doi.org/10.1155/2018/1254602
Johnson K, Stoffel B, Schwitter M, et al. Prevention of taxane chemotherapy‑induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single‑centre study with intrapatient comparison. Supportive Care in Cancer (2024) 32:554.
https://doi.org/10.1007/s00520-024-08737-3
Zhi WI, Chen P, Alice Kwon A, et al. Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing. Breast Cancer Res Treat. 2019; 178(3): 587–595.
https://doi.org/10.1007/s10549-019-05416-4
Li T, Timmins HC, Trinh T, et al. Patient-reported outcome measures in chemotherapy-induced peripheral neurotoxicity: defining minimal and clinically important changes. J Natl Compr Canc Netw 2023;21(2):125–132.e3
https://doi.org/10.6004/jnccn.2022.7074
Saad, M., Psimaras, D., Tafani, C. et al. Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy. J Neurooncol 2016 ;127, 373–380.
https://doi.org/10.1007/s11060-015-2049-x
Nikolaou V, Syrigos K, & Saif MW. Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf. 2016 Dec ;15(12):1625-1633.
https://doi.org/10.1080/14740338.2016.1238067
Kwakman JJM, Elshot YS, Punt CJA, & Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev. 2020 May 13;14(1):442.
https://doi.org/10.4081/oncol.2020.442
Fumoleau P, Largillier R, Clippe C, Dièras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Curé H, Vuillemin E, Morère JF, Montestruc F, Mouri Z, & Namer M. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004 Mar;40(4):536-42.
https://doi.org/10.1016/j.ejca.2003.11.007
Miller KK, Gorcey L, & McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, aetiology, pathogenesis, and management. J Am Acad Dermatol. 2014 Oct;71(4):787-94.
https://doi.org/10.1016/j.jaad.2014.03.019
Sibaud V, Dalenc F, Chevreau C, Roché H, Delord JP, Mourey L, Lacaze JL, Rahhali N, Taïeb C. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist. 2011;16(10):1469-78.
https://doi.org/10.1634/theoncologist.2011-0033
Baskarane H, Sahni S, Nagpal C, Divakar MK, Pathak N, Kumar S, Bakhshi S, Sagiraju HKR, Singh PP, Agarwal R, Hooda V, Vasudeva P, & Batra A. Preventing Hand-Foot Syndrome in patients with cancer: A systematic review and network meta-analysis. JAMA Dermatol. 2026 Apr 1;162(4):386-394.
https://doi.org/10.1001/jamadermatol.2026.0042
Delaloge S, Piccart M, Rutgers E, Litière S, et al.Standard anthracycline based Versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. J Clin Oncol. 2020 Apr 10;38(11):1186-1197.
https://doi.org/10.1200/JCO.19.01371
Bun S, Yunokawa M, Tamaki Y, Shimomura A, Shimoi T, Kodaira M, Shimizu C, Yonemori K, Fujiwara Y, Makino Y, Terakado H, Tamura K. Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer. Support Care Cancer. 2018 Jul;26(7):2161-2166.
https://doi.org/10.1007/s00520-018-4054-z
Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ, & Chen G. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol. 2012 May;23(5):1348-1353.
https://doi.org/10.1093/annonc/mdr400
Santhosh A, Sharma A, Bakhshi S, Kumar A, Sharma V, Malik PS, Pramanik R, Gogia A, Prasad CP, Sehgal T, Gund S, Dev A, Cheung WY, Pandey RM, Kumar S, Gupta I, Batra A; D-TORCH Trial Investigators. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial. J Clin Oncol. 2024 May 20;42(15):1821-1829.
https://doi.org/10.1200/jco.23.01730
Gialaim Purcino Dos Reis FC, Menêses AG, Mazoni SR, Pereira Silveira RCC, Diniz Dos Reis PE, & Vasques CI. Topical interventions for preventing hand-foot syndrome resulting from antineoplastic therapy: A scoping review. Rev Esc Enferm USP. 2023 Nov 10;57:e20220107.
https://doi.org/10.1590/1980-220x-reeusp-2023-0107en
Lian S, Zhang X, Zhang Y, & Zhao Q. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis. Clin Exp Dermatol. 2021 Jun;46(4):629-635.
https://doi.org/10.1111/ced.14486
Piwnica D, Rosignoli C, Thibaut de Menonville S, et al. Vasoconstriction and anti-inflammatory properties of the selective alpha-adrenergic receptor agonist brimonidine. J Dermatol Sci. 2014;75(1):49–54.
https://doi.org/10.1016/j.jdermsci.2014.04.002
Bertino B, Blanchet-Réthoré S, Thibaut de Ménonville S, Reynier P, Méhul B, Bogouch A, Gamboa B, Dugaret AS, Zugaj D, Petit L, Roquet M, Piwnica D, Vial E, Bourdès V, Voegel JJ, Nonne C. Brimonidine displays anti-inflammatory properties in the skin through the modulation of the vascular barrier function. Exp Dermatol. 2018 Dec;27(12):1378-1387.
https://doi.org/10.1111/exd.13793
Hsia E, Tian M, Gil D. Reduction in ultraviolet B light-induced erythema by oxymetazoline and brimonidine is mediated by different α-adrenoceptors. Exp Dermatol. 2018;27(8):763–768.
https://doi.org/10.1111/exd.13557
Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, Liu Y, Leoni M; Brimonidine Phase II Study Group. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012 Mar;166(3):633-41.
https://doi.org/10.1111/j.1365-2133.2011.10716.x
Fowler J Jr, Jackson M, Moore A, Jarratt M, Jones T, Meadows K, Steinhoff M, Rudisill D, Leoni M. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013 Jun 1;12(6):650-6. PMID: 23839181. https://jddonline.com/articles/efficacy-and-safety-of-once-daily-topical-brimonidine-tartrate-gel-05-for-the-treatment-of-moderate-S1545961613P0650X/
Layton AM, Schaller M, Homey B, et all. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. JEADV 2015, 29, 2405–2410.
https://doi.org/10.1111/jdv.13305
Johnson A. Johnson SA. The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea. Dermatol Ther (Heidelb) (2015) 5:171–181
https://doi.org/10.1007/s13555-015-0078-1
Czernielewski J, Winckle G, Andres P. A new extended-release topical formulation of brimonidine tartrate — first clinical evaluation and perspectives. Abstract 2115. EADV Congress, Paris, September 2025
A new extended-release Topical Formulation of Brimonidine Tartrate – First Clinical Evaluation and Perspectives
Andres P, Winckle G, Lamquin A, Czernielewski J. TAR-0520 gel: A novel treatment for the prevention of chemotherapy-induced skin toxicities. Support Care Cancer. 2025;33(Suppl 1): S197.
https://doi.org/10.1007/s00520-025-09559-7
Andres P, Winckle G, Lamquin A, Czernielewski J. TAR‑0520, a new candidate in oncodermatology: Results of a phase 1 program in healthy volunteers. Supportive Care in Cancer (2026) 34:649
https://doi.org/10.1007/s00520-026-10878-6
